ALEMBICLTD

Alembic Share Price

₹139.47 -5.87 (-4.04%)

21 Dec, 2024 18:46

SIP TrendupStart SIP in ALEMBICLTD

Start SIP

Performance

  • Low
  • ₹138
  • High
  • ₹149
  • 52 Week Low
  • ₹78
  • 52 Week High
  • ₹169
  • Open Price₹146
  • Previous Close₹145
  • Volume956,202

Investment Returns

  • Over 1 Month + 11.34%
  • Over 3 Month -2.32%
  • Over 6 Month + 35.67%
  • Over 1 Year + 57.42%
SIP Lightning

Smart Investing Starts Here Start SIP with Alembic for Steady Growth!

Invest Now

Alembic Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 11.5
  • PEG Ratio
  • 0.3
  • Market Cap Cr
  • 3,581
  • P/B Ratio
  • 1.6
  • Average True Range
  • 5.86
  • EPS
  • 12.09
  • Dividend Yield
  • 1.7
  • MACD Signal
  • 3.26
  • RSI
  • 51.44
  • MFI
  • 71.7

Alembic Financials

Alembic Technicals

EMA & SMA

Current Price
₹139.47
-5.87 (-4.04%)
pointer
  • stock-down_img
  • Bullish Moving Average 9
  • stock-up_img
  • Bearish Moving Average 7
  • 20 Day
  • ₹139.91
  • 50 Day
  • ₹137.02
  • 100 Day
  • ₹134.35
  • 200 Day
  • ₹124.81

Resistance and Support

142.21 Pivot Speed
  • R3 156.81
  • R2 152.86
  • R1 146.16
  • S1 135.51
  • S2 131.56
  • S3 124.86

What's your outlook on Alembic?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Alembic Ltd. is a leading Indian pharmaceutical and healthcare company, specializing in the manufacturing of generic and branded formulations, active pharmaceutical ingredients (APIs), and bulk drugs. The company focuses on quality, innovation, and research to meet global healthcare needs.

Alembic (Nse) has an operating revenue of Rs. 192.06 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 65% is great, ROE of 12% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 19% from 50DMA and 200DMA. It is currently FORMING a base in its weekly chart and is trading around 14% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at B+ which is evident from recent demand for the stock, Group Rank of 50 indicates it belongs to a fair industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has mediocre technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Alembic Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-11-08 Quarterly Results & Other To Consider other business matters. per share(30%)Final Dividend
2024-08-12 Quarterly Results
2024-05-13 Audited Results & Final Dividend
2024-02-14 Quarterly Results
2023-11-08 Quarterly Results
Date Purpose Remarks
2024-08-05 FINAL Rs.2.40 per share(120%)Final Dividend
2023-08-03 FINAL Rs.2.20 per share(110%)Final Dividend
2022-09-13 FINAL Rs.1.80 per share(90%)Dividend

Alembic F&O

Alembic Shareholding Pattern

70.88%
1.97%
0.04%
21.56%
5.55%

About Alembic

  • NSE Symbol
  • ALEMBICLTD
  • BSE Symbol
  • 506235
  • Managing Director & CEO
  • Mrs. Malika Amin
  • ISIN
  • INE426A01027

Similar Stocks to Alembic

Alembic FAQs

Alembic share price is ₹139 As on 21 December, 2024 | 18:32

The Market Cap of Alembic is ₹3581.3 Cr As on 21 December, 2024 | 18:32

The P/E ratio of Alembic is 11.5 As on 21 December, 2024 | 18:32

The PB ratio of Alembic is 1.6 As on 21 December, 2024 | 18:32

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23